0 works0 citations0 h-index

Lucy Kilburn

Institute of Cancer Research(GB)Cancer Research UK(GB)Institute of Cancer Research(CA)Cancer Research UK Clinical Trials Unit(GB)

Publications by Year

Research Areas

Cancer Genomics and Diagnostics, Estrogen and related hormone effects, Advanced Breast Cancer Therapies, Breast Cancer Treatment Studies, Lung Cancer Treatments and Mutations

Most-Cited Works

→ Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial(2007)908 cited
→ Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial(2018)889 cited
→ Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study(2011)708 cited
→ Plasma ESR1 Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer(2016)703 cited
→ Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study(2007)425 cited

→ Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial(2020)

340 cited

→ Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial(2020)302 cited

→ Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial(2013)272 cited

→ Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer(2022)179 cited

→ Abstract S3-01: The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012)(2015)164 cited